31 March 2026
Anpario plc (“Anpario”, “Group” or the “Company”) Final results Anpario plc (AIM: ANP), the independent manufacturer of natural and sustainable feed additives for animal…
Unilever PLC Response to Media Speculation Further to the announcement released on 20 March 2026, the Board of Unilever PLC (the “Company”) notes recent…
Efzimfotase alfa demonstrated positive results from global Phase III clinical programme in hypophosphatasia MULBERRY randomised, placebo-controlled trial showed efzimfotase alfa demonstrated statistically significant and clinically meaningful improvement…
30 March 2026
HICL Infrastructure PLC “HICL” or “the Company” and, together with its subsidiaries, “the Group”, the London-listed infrastructure investment company managed by InfraRed Capital Partners…
Bepirovirsen accepted for regulatory review in China as a potential first-in-class functional cure for chronic hepatitis B GSK plc (LSE/NYSE: GSK) today announced that the…
Exdensur (depemokimab) approved in China for the treatment of severe asthma GSK plc (LSE/NYSE: GSK) today announced that China’s National Medical Products Administration (NMPA) has…
25 March 2026
25 March 2026 HICL Infrastructure PLC “HICL” or “the Company” and, together with its subsidiaries, “the Group”, the London-listed infrastructure investment company managed by…
James Latham plc (“James Latham” or “the Company”) Trading Statement The Board of James Latham provides the following trading statement ahead of the Company’s…